Prednisone Withdrawal Versus Prednisone Maintenance After Kidney Transplant

Transplants and Implants Clinical Trial

Official title:

Randomized, Prospective Single-center Study Comparing a Rapid Discontinuation of Corticosteroids (Steroid Withdrawal) With Corticosteroid Therapy in Kidney Transplantation Using Mycophenolate Mofetil and Tacrolimus Maintenance Therapy

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00596947
• Other study ID #: 803242
• Status: Terminated
• Phase: Phase 4
• First received: January 8, 2008
• Last updated: February 18, 2011
• Start date: October 2005
• Est. completion date: March 2009

Study information

• Verified date: February 2011
• Source: University of Pennsylvania
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of the study was to determine if rapid discontinuation of corticosteroids (also known as prednisone withdrawal) and maintenance immunosuppression with Prograf (tacrolimus) and CellCept (mycophenolate mofetil) while using Thymoglobulin (Rabbit antithymocyte globulin) will give similar safety and efficacy results compared to continuation of corticosteroids (also known as prednisone maintenance) and standard maintenance immunosuppression with Prograf (tacrolimus), CellCept (mycophenolate mofetil) while using Thymoglobulin (Rabbit antithymocyte globulin).

Description:

Corticosteroids (one specific type is prednisone) have been used in clinical transplantation for more than 30 years. There are many side effects of corticosteroids including significant bone disease, diabetes (elevated blood sugar levels), fluid retention and hypertension (high blood pressure), psychosis, peptic ulcer disease, hyperlipidemia (elevated lipid levels such as cholesterol and triglycerides), obesity (overweight), acne, and susceptibility to infections. It is hoped that the new generation of potent immunosuppressive medications (such as Prograf and CellCept) will permit avoidance or withdrawal of corticosteroids for the majority of patients to avoid both short- and long-term complications of corticosteroid use in kidney transplant recipients.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 18
• Est. completion date: March 2009
• Est. primary completion date: March 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 19 Years to 74 Years

Eligibility

Inclusion Criteria:

• First time kidney transplant recipients who receives a kidney from a cadaveric, living related or living unrelated donor

• Age greater than 18 years and less than 75 years

• Caucasian recipients

• Patients with current low panel reactive antibody (PRA) levels (<10%)

• Patients with signed and dated informed consent

• Women of childbearing potential must have a negative pregnancy test at baseline and agree to use a medically acceptable method of contraception throughout the treatment period.

Exclusion Criteria:

• Other than Caucasian ethnicity

• Patients with HIV+ or

• Patients with HbsAg+ or Hepatitis C positive

• Patients with a history of malignancy in the past 5 years

• Patients with active systemic or localized major infection

• Patients with a history of chronic steroid use for other diseases

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Transplants and Implants

Intervention

Drug:
• prednisone
In this group, participants had prednisone rapidly decreased until completely eliminated by day 6 after transplant. Participants began on 500mg of intravenous methylprednisolone on the day of transplant, followed by the following doses of oral prednisone: 160mg on day 1, 120mg on day 2, 80mg on day 3, 40mg on day 4, 20mg on day 5, none from day 6-on.
• rabbit antithymocyte globulin
Participants in both groups received 3 to 5 doses of an intravenous medication to prevent rejection called Thymoglobulin (rabbit antithymocyte globulin) as per our standard of care. This drug was dosed at 1.5 milligrams/killograms per dose and dosing was then based on body weight. The dose was decreased in half or held if the participant had a low white blood cell count or if the participant a low platelet count. The first dose was given intravenously in the operating room and subsequent intravenous doses were administered either while participants were inpatients or outpatients for a total of 3 to 5 doses for a total of up to 6mg/kg. The number of doses was based on transplant kidney function and risk factors for rejection.
• Tacrolimus
Participants in both groups received tacrolimus per our standard of care. This medication helped to prevent rejection and was initially dosed at 0.1-0.2 milligrams/killograms/day in two divided doses, given orally, based on participant's body weight. We then looked at the trough levels of this medication(the lowest level before the next dose), and aimed to keep the trough level between 5-10 nanograms/milliliter throughout the study.
• Prednisone
Participants in this group continued on prednisone indefinitely. Participants began with 500mg of intravenous methylprednisolone on the day of transplant, followed by the following doses of oral prednisone: 160mg on day 1, 120mg on day 2, 80mg on day 3, 40mg on day 4, 20 mg days 5-9, 15 mg day 10-19, 10 mg day 20-24, 7.5 mg day 25-29, and 5mg from day 30-on indefinitely.
• Mycophenolate mofetil
Participants in both groups received mycophenolate mofetil by mouth twice daily indefinitely. Dosing for patients in the Prednisone withdrawal group was 1000mg orally twice daily. The dose was decreased or held at the discretion of the physician, for side effects such as low white blood cell count, or low platelet count, or if the participant experienced stomach side effects such as heartburn, nausea, vomiting or diarrhea.
• Mycophenolate mofetil
Participants in both groups received mycophenolate mofetil by mouth twice daily indefinitely. Dosing for patients in the Prednisone maintenance group was 500 mg orally twice daily. The dose was decreased or held at the discretion of the physician, for side effects such as low white blood cell count, or low platelet count, or if the participant experienced stomach side effects such as heartburn, nausea, vomiting or diarrhea.

Locations

Country	Name	City	State
United States	Hospital of the University of Pennsylvania	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
University of Pennsylvania

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Number of Participants With Acute Rejection Episodes	Acute rejection episodes would have been measured by the number of participants who underwent a kidney transplant biopsy, and had the results of the biopsy reported as acute rejection by the transplant pathologist. Biopsies were only performed if clinically indicated. The cumulative number of participants with recorded rejection episodes by 6 and 12 months post-transplant would have been reported.	6 and 12 months post-transplant	No
Primary	The Number of Participants With Graft Survival	The number of participants who did not experience graft failure (defined as return to dialysis) at 6 and 12 months would have been reported.	6 and 12 months	No
Primary	Participant Survival	The number of participants alive at 6 and 12 months post-transplant would have been posted as a measure of patient survival.	6 and 12 months	No
Secondary	The Number of Participants With Treatment Failures	This measure was defined as the percentage of participants that did not remain on initial therapy (ie were withdrawn from each arm of the trial)	12 months	Yes
Secondary	Length of Hospital Stay After Transplant	The length of the hospital stay would have assessed the number of days a participant was in the hospital after the kidney transplant was performed. This is calculated from date of admission to date of discharge.	12 months	Yes
Secondary	The Number of Participants With Hospital Readmissions	The number of readmissions during the study period for each participant would have been assessed, as well as the reason for readmissions.	12 months	Yes
Secondary	The Length of Stay Associated With Hospital Readmissions	The time from admission to discharge for each readmission for patients readmitted in the first 12 months post-transplant.	12 months	Yes
Secondary	Participant Renal Function as Measured by MDRD Formula	The above methods focus on estimating or determining actual glomerular filtration rate (GFR) (or renal function) of the kidney transplant. The MDRD (Modification of Diet in Renal Disease) calculation includes age, sex and serum creatinine would have provided an estimate of GFR. This was to be performed at 3,6 and 12 months post-transplant.	3, 6 and 12 months	Yes
Secondary	Participant Renal Function as Measured by 24 Hour Urine Collection	Results would have been reported from patients undergoing 24 hour urine collections at 3 and 12 months post-transplant. This is a way to measure glomerular function rate (GFR) or renal function.	3 and 12 months post-transplant	Yes
Secondary	The Number of Participants With the Need for Rabbit Antithymocyte Globulin to Treat Rejection Episodes.	The incidence and severity of rejection episodes per participant would have been identified by kidney transplant biopsy results read by a transplant pathologist. Treatment of rejection episodes in each participant would have been determined by the treating transplant physician.	12 months	Yes
Secondary	The Number of Participants With Leukopenia	All participants would have been assessed for the presence at any time during the trial of: leukopenia (defined by lab results as a white count less than 3,000 cells/uL).	12 months	Yes
Secondary	The Number of Participants With Infections	Participants would have been monitored throughout the study for any infectious complications as confirmed by the principal investigator. Patients would have been monitored by urine cytology and blood polymerase chain reaction for BK virus at baseline, and months 3, 6 and 12 post-transplant.	12 months	Yes
Secondary	The Number of Participants With Malignancy	Participants would have been monitored throughout the study with any reports of malignancy being confirmed by principal investigator.	12 months	Yes
Secondary	The Number of Participants With Hypertension	The number of participants who developed hypertension defined as blood pressure greater than 140/90 throughout the first 12 months of the study.	12 months	Yes
Secondary	The Number of Participants With Hyperlipidemia	Fasting lipid profiles were to be performed at 3,6 and 12 months post-transplant. Definitions based on ATP III guidelines.	12 months	Yes
Secondary	The Number of Participants With Bone Disease	Bone densitometry by Computed tomography of peripheral skeleton and DEXA scans were performed at baseline (within one month after transplant) Urine and blood samples to measure markers of bone turnover: Alkaline phosphatase, pyridinoline, serum 1-25 vit D 3 levels (calcitriol) and 25 hydroxy vit D (calcidiol) levels and serum osteocalcin levels were drawn at baseline, 3, 6, 12 and 24 months.	baseline (within 1 month post-transplant), 3, 6, 12 and 24 months	Yes
Secondary	The Number of Participants With Post Transplant Diabetes Mellitus	Glucose tolerance test performed in non-diabetic participants only at pre transplant in living donor recipients and at baseline (within 1 mo after transplant) and 6 mo and 12 months. Blood test for hemoglobin A1C in non diabetic participants only: at baseline, 3, 6, and 12 months.; Insulin and C peptide levels at baseline, 3,6 and 12 months in all participants.	pre-transplant in living donor recipients, baseline (within one month post-transplant) and at 3, 6 and 12 months	Yes
Secondary	The Number of Participants With Weight Gain	Height, weight will be used to calculate change in BMI for all participants.	12 months	Yes